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Abstract An increased prevalence of autoimmune dis-
eases in family members of children with autism spectrum
disorders (ASD) has been previously reported. ASD is also
a common problem co-occurring in children with fragile X
syndrome (FXS). Why ASD occurs in some individuals
with FXS, but not all, is largely unknown. Furthermore, in
premutation carrier mothers, there is an increased risk for
autoimmune diseases. This study compared the rate of ASD
and other neurodevelopmental/behavioral problems in 61
children with FXS born to 41 carrier mothers who had auto-
immune disease and in 97 children with FXS of 78 carrier
mothers who did not have autoimmune disease. There were
no signiWcant diVerences in the mean age (9.61 § 5.59 vs.
9.41 § 6.31, P = 0.836), cognitive and adaptive function-
ing in children of mothers with and without autoimmune
disease. Among children whose mothers had autoimmune
disease, the odds ratio (OR) for ASD was 1.27 (95% CI
0.62–2.61, P = 0.5115). Interestingly, the OR for seizures
and tics was 3.81 (95% CI 1.13–12.86, P = 0.031) and 2.94
(95% CI 1.19–7.24, P = 0.019), respectively, in children of
mothers with autoimmune disease compared to children of
mothers without autoimmune disease. In conclusion, auto-
immune disease in carrier mothers was not associated with
the presence of ASD in their children. However, seizures
and tics were signiWcantly increased in children of mothers
with autoimmune disease. This suggests a potential new
mechanism of seizure and tic exacerbation in FXS related
to an intergenerational inXuence from autoimmunity in the
carrier mother.
Introduction
There is a close connection between immune function and
development of the central nervous system (CNS). Both
systems interact across the life span of an individual so that
successful neurodevelopment requires a normal balance of
immune responses (Ashwood et al. 2006; Delneste et al.
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1999). Autism spectrum disorders (ASD) are a complex
group of heterogeneous neurodevelopmental disorders with
signiWcant social and communication deWcits in which eti-
ologies are mostly unknown. Recently, altered immunoge-
netics and a dysfunctional immune system have been
proposed to play a role in at least a subgroup of children
with ASD (Ashwood et al. 2006; Enstrom et al. 2009). In
addition, an increased prevalence of autoimmune disease in
family members of children with idiopathic ASD has been
demonstrated in several studies (Atladottir et al. 2009;
Comi et al. 1999; Money et al. 1971; Sweeten et al. 2003).
Maternal autoantibodies may also aVect fetal brain devel-
opment during critical periods of neurodevelopment in a
subset of children with ASD (Ashwood and Van de Water
2004; Dalton et al. 2003; Singer et al. 2006). Studies have
shown that when IgG from mothers of children diagnosed
with ASD is injected into pregnant rhesus monkeys, there
are behavioral changes in the rhesus oVspring including
abnormal stereotypical and hyperactive behaviors, com-
pared with oVspring injected with IgG isolated from moth-
ers of typically developing children and controls (Martin
et al. 2008). These Wndings suggest a potential deleterious
relationship between exposure to autoantibodies against the
fetal brain during gestation and the risk to develop ASD.
Fragile X syndrome (FXS) is the most common known
single gene cause of autism (Hagerman et al. 2008). The
prevalence of autism in individuals with FXS is approxi-
mately 30% (Kaufmann et al. 2004; Rogers et al. 2001) and
pervasive developmental disorder-not otherwise speciWed
(PDD-NOS) is seen in an additional 30% (Harris et al.
2008). Therefore, the prevalence of ASD is approximately
60% in individuals with FXS (Hagerman et al. 2008; Harris
et al. 2008). The mechanism of ASD in FXS is hypothe-
sized to be related to the deWcit of FMRP (the FMR1 pro-
tein) which regulates the translation of many genes that are
associated with autism (Chonchaiya et al. 2009; Hagerman
et al. 2008; Wang et al. 2010). Why ASD occurs in some
individuals with FXS, but not all, is largely unknown
(Loesch et al. 2007). Problems aVecting the CNS including
seizures, malformations, or other genetic disorders are
more likely to occur in those with FXS and ASD compared
with those with FXS without ASD (Garcia-Nonell et al.
2008). Therefore, the diagnosis of ASD in those with FXS
may also be related to additional risks including genetic and
environmental factors leading to additional brain dysfunc-
tion additive to the FMR1 mutation (Loesch et al. 2007).
The prevalence of autoimmune diseases including auto-
immune thyroid disease, lupus, multiple sclerosis (MS),
and Wbromyalgia (with a postulated autoimmune compo-
nent) are increased in females with the FMR1 premutation
(Buskila and Sarzi-Puttini 2008; CoVey et al. 2008; Di
Franco et al. 2010; Greco et al. 2008; Rodriguez-Revenga
et al. 2009; Staines 2004; Zhang et al. 2009). These autoim-
mune disorders in some premutation carriers are thought to
be related to RNA toxicity from elevated levels of FMR1
mRNA (CoVey et al. 2008; Greco et al. 2008; Zhang et al.
2009). Maternal autoimmunity may play an additional role
that further contributes to ASD or may be associated with
more severe ASD symptoms along the continuum of social
deWcits in their children with FXS. However, the associa-
tion between autoimmune disease in mothers and the pres-
ence of ASD or other medical and behavioral problems
particularly tics [since tics and Tourette syndrome have a
potential autoimmune etiology through the mechanism of
pediatric autoimmune neuropsychiatric disorders associ-
ated with streptococcal infection (PANDAS) (Martino et al.
2009a)] that perhaps could be inXuenced by autoimmunity
in their children with FXS has not been studied previously.
We therefore investigated whether autoimmune diseases/
conditions in mothers with the FMR1 premutation are asso-
ciated with ASD or other problems by comparing the
oVspring of mothers with and without autoimmune disease
(M + AI and M ¡ AI).
Materials and methods
Subjects
Included in this study were children with FXS (n = 158)
with either the full mutation or mosaicism, and their moth-
ers (n = 119) whom were seen between 2003 and 2009 at
the MIND Institute. This study was approved by the Institu-
tional Review Board of the University of California, Davis.
The children with FXS in this cohort were divided into chil-
dren (n = 61) who were born to mothers who had a history
of autoimmune disease and children (n = 97) whose moth-
ers did not have autoimmune disease.
The diagnosis of autoimmune disease in the mother was
conWrmed by a physician and these diseases include auto-
immune thyroid disease, systemic lupus erythematosus
(SLE), rheumatoid arthritis, multiple sclerosis (MS), Sjo-
gren’s syndrome, psoriasis, optic neuritis, Raynaud’s phe-
nomenon, or Wbromyalgia, which has a postulated
autoimmune component in its pathophysiology (CoVey
et al. 2008; Di Franco et al. 2010; Greco et al. 2008; Staines
2004; Zhang et al. 2009). Sixty-one children with FXS with
a mean age of 9.61 years (SD 5.59) were born to 41 moth-
ers with a mean age of 40.54 years (SD 7.96) who had
experienced autoimmune disease. They were compared to
97 children with FXS with a mean age of 9.41 years (SD
6.31), born to 78 mothers with a mean age of 38.62 years
(SD 6.46) without a history of clinically deWned autoim-
mune disease. Most mothers in each group [M + AI and
M ¡ AI, 23 (56.1%) vs. 59 (75.6%), respectively] had one
child with FXS. There were 16 (39.0%) and 19 (24.4%)Hum Genet (2010) 128:539–548 541
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M+A I  a n d  M¡ AI, respectively, who had two children
with FXS. Two (4.9%) M + AI had three children with
FXS. Children with the FMR1 premutation born to these
mothers were not included in the study. A description of
both mothers and children with FXS are presented in
Tables 1 and 2.
Study protocol
All subjects underwent a full medical history and physi-
cal examination by a physician with expertise in fragile
X-associated disorders (RJH) after informed consent was
obtained. The medical history covered an extensive review
of prenatal, perinatal and postnatal history and complica-
tions, developmental and behavioral variations and prob-
lems for each child including developmental delay or
regression of development, tics (a sudden, repetitive, non-
rhythmic, stereotyped motor movement or vocalization
involving discrete muscle groups, such as eye blinking,
shoulder shrugging, throat clearing, etc.; tics symptoms had
to appear before 18 years of age and occur before taking
stimulant medications if those with FXS also have co-morbid
attention deWcit/hyperactivity disorders), sleep problems
(problems falling asleep or waking up at night), clinical sei-
zures (seizures characteristics, onset, duration, frequency,
any co-occurring loss of consciousness, other neurological
deWcit, associated symptoms, possible triggers if they could
be deWned, electrical activity recorded by an electroenceph-
alography (EEG) testing, and anticonvulsant medications),
other pertinent medical problems, review of systems, and
medications. Autoimmune diseases/conditions in mothers
were thoroughly obtained by self-report after questioning
about all potential autoimmune disorders in the medical
history mentioned above. Sometimes medical records
(approximately 30%) of the mothers were available for
review in those with autoimmune problems during the vis-
its at our clinic; however, these data are not included in the
analysis because it was not consistently obtained. To be
documented as having an autoimmune disease in the
mother or developmental, behavioral, and medical prob-
lems particularly seizures, tics, and sleep problems in chil-
dren with FXS, the subjects had to have sought medical or
pediatric professional help for their problems and to have
been previously diagnosed and/or treated by a physician for
each disease/condition (physician-documented clinical
involvement). Each subject underwent a medical examination
Table 1 Characteristics of 
mothers with the fragile 
X premutation
Variables Mother with 
autoimmune disease1 
Mean (SD)
Mother without 
autoimmune disease0 
Mean (SD)
N1/N0 P
Age (years)
Age range
40.54 (7.96)
(30–66)
38.62 (6.46)
(24–58)
41/78 0.238
CGG repeats 97.59 (20.31) 96.30 (23.05) 27/60 0.687
Activation ratio 0.57 (0.14) 0.56 (0.17) 26/54 0.146
FMR1 mRNA 2.74 (0.75) 2.55 (0.78) 24/44 0.773
Table 2 Characteristics of 
children with FXS
Variables Children of mothers 
with autoimmune 
disease1 
Mean (SD)
Children of mothers 
without autoimmune 
disease0 
Mean (SD)
N1/N0 P
Age (years)
Age range
9.61 (5.59)
(1.5–24)
9.41 (6.31)
(0.92–25.17)
61/97 0.836
Male 60.7% 78.4% 61/97 0.016*
Type of fragile X mutation (%) 
full mutation:mosaicism
48:13 (78.7:21.3) 77:20 (79.4:20.6) 61/97 0.876
CGG repeat levels 651.30 (246.98) 732.49 (321.52) 33/65 0.207
mRNA levels 1.10 (0.92) 1.05 (1.64) 10/37 0.927
Full scale IQ 62.75 (17.77) 60.80 (17.55) 56/83 0.523
Vineland-II
Adaptive behavioral composite 64.33 (18.51) 63.62 (18.71) 42/66 0.847
Communication 69.05 (20.58) 66.52 (21.00) 41/67 0.542
Daily living skills 64.76 (21.92) 64.90 (21.48) 41/67 0.974
Socialization 69.20 (15.70) 69.42 (15.86) 41/67 0.943
Motor 73.14 (14.84) 72.09 (17.36) 21/35 0.817
*S i g n i Wcant at 0.05 level542 Hum Genet (2010) 128:539–548
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that included a head circumference. A large head or macro-
cephaly was deWned as exceeding 2 standard deviations
(SD) above normal when compared with typically develop-
ing children of the same age.
The diagnosis of ASD in those with FXS was made after
the use of standardized measures including the Autism
Diagnostic Observation Schedule (ADOS), the Autism
Diagnostic Interview, Revised (ADI-R) and the Diagnostic
and Statistical Manual of Mental Disorders (DSM IV)
(American Psychiatric Association 2000; Le Couteur et al.
1989; Lord et al. 2000) followed by a team consensus dis-
cussion as previously described (Harris et al. 2008).
The developmental or cognitive abilities were assessed
with age appropriate measures, including the Mullen Scales
of Early Learning, the Wechsler Preschool and Primary
Scale of Intelligence-Third Edition (WPPSI-III), the
Wechsler Intelligence Scale for Children-Third Edition
(WISC-III), the Wechsler Intelligence Scale for Children-
Fourth Edition (WISC-IV), the Wechsler Abbreviated
Scale of Intelligence (WASI), the Wechsler Adult Intelli-
gence Scale-Third Edition (WAIS-III) or the Stanford-
Binet Intelligence Scale, Fourth Edition. Children’s
adaptive functioning was also assessed using the Vineland
Adaptive Behavioral Scales, Second Edition (Vineland-II)
by interviewing the caregivers (Mullen 1995; Sparrow et al.
2005; Thorndike et al. 1986; Wechsler 1991, 1997, 1999,
2002, 2003). Intellectual disability was deWned as IQ less
than 70.
Behavioral and emotional problems including external-
izing behaviors (hyperactivity, aggression, and conduct
problems), internalizing behaviors (anxiety, depression,
and somatization), atypicality, withdrawal, attention
problems, and adaptive skills (adaptability, social skills,
leadership, activities of daily living, and functional commu-
nication) were completed by a limited percentage of parents
for each group of children with FXS (autoimmune disease
vs. no autoimmune disease, 72.1 vs. 54.6%) using Behavior
Assessment System for Children (BASC) questionnaire
(Reynolds and Kamphaus 1992,  2004). Behavior Symp-
toms Index (BSI), a measure of an overall level of problems
consisting of the hyperactivity, aggression, depression,
attention problems, atypicality and withdrawal scales, was
also documented. The BASC parent rating scale yields
T scores with a mean of 50 and a SD of 10. On the clinical
scales, scores from 60 to 69 are in the “at-risk” range and
scores of 70 and above indicate “clinically signiWcant”
problems. On the adaptive skill scales of the BASC, scores
from 31 to 40 indicate “at-risk” problems and scores of 30
and lower are considered “clinically signiWcant.” In this
study, externalizing, internalizing behaviors, and BSI
scores 60 or above were deWned as having those problems
accordingly, whereas deWcits in adaptive skills were deW-
ned in which adaptive skills scores are 40 or lower. Table 3
lists the variables investigated statistically between both
groups of children.
Molecular analysis
A blood sample for measurement of methylation status,
CGG repeat, and FMR1 mRNA levels were obtained from
each subject (both mothers and children with FXS). FMR1
mRNA quantiWcation, Southern Blot and PCR-based
Table 3 Neurodevelopmental and behavioral problems between both groups of children
*S i g n i Wcant at 0.05 level
a Results are similar for all analyses with gender, except for BSI where P = 0.0225
Variables Children of mothers 
with autoimmune 
disease1
Children of mothers 
without autoimmune 
disease0
N1/N0 P Odds 
ratio
95% CI
ASD diagnosis 38 (62.3%) 56 (57.73%) 61/97 0.5115 1.27 0.62–2.61
Autism 22 (36.07%) 31 (31.96%)
PDDNOS 16 (26.23%) 25 (25.77%)
Intellectual disability 41 (68.33%) 75 (78.13%) 60/96 0.1464 0.59 0.29–1.2
BASC
Externalizing behaviors 16 (36.36%) 9 (16.98%) 44/53 0.0319* 3.04 1.10–8.38
Internalizing behaviors 13 (29.55%) 8 (15.09%) 44/53 0.1081 2.29 0.83–6.31
BSI 31 (72.09%) 29 (55.77%) 43/52 0.1045a 2.04 0.86–4.8
DeWcits in adaptive skills 32 (72.73%) 39 (73.58%) 44/53 0.9101 0.95 0.37–2.43
Seizures 9 (15%) 4 (4.21%) 60/95 0.031* 3.81 1.13–12.86
Sleep problems 24 (42.86%) 35 (38.04%) 56/92 0.6626 1.17 0.58–2.38
Tics 15 (25.86%) 10 (10.64%) 58/94 0.019* 2.94 1.19–7.24
Macrocephaly 4 (7.14%) 7 (7.53%) 56/93 0.9531 0.96 0.23–3.97Hum Genet (2010) 128:539–548 543
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genotyping were performed as previously described
(Tassone et al. 2000; Tassone et al. 2008).
Statistical analysis
Qualitative variables for which there were speciWed cut-oVs
including autoimmune disease in mothers, the diagnosis of
ASD, intellectual disability, seizures, sleep problems, tics,
macrocephaly, externalizing, internalizing behaviors, BSI and
deWcits in adaptive skills were rated dichotomously (presence
or absence) as demonstrated in Table 3. Univariate analysis of
continuous variables including age, CGG repeat size, FMR1
mRNA level, activation ratio (AR: the fraction of normal
FMR1 allele as the active allele in female individuals with
FXS), IQ, and adaptive functioning was based on t test.
Fisher’s exact test for 2 £ 2 contingency table analyses were
used to assess the association between autoimmune status in
the mothers of children with FXS and the diagnosis of ASD.
Results are presented in terms of odds ratio (OR) and 95%
conWdence interval (95% CI). P value and 95% conWdence
interval (CI) relating to the primary hypotheses of whether
there is an association of autoimmune disease in mothers to
ASD in children with FXS was based on a logistic regression
model using generalized estimating equations. This approach
accounts for correlation within a family (i.e. mother–children
correlation) in estimates of standard errors, although this did
not make a material diVerence in the results. Also, models
were explored with adjusting for mother’s age, child’s age,
gender, number of oVspring, whether a mother had a child
before or after age 35, CGG repeat numbers, and mRNA lev-
els. All covariates were not signiWcant and adjusted OR esti-
mates did not diVer from OR estimates from models with
only the main variable of interest—the presence of autoim-
mune disease. Thus, we reported this simple later model with
main eVect of interest. An exception is for the variable gender
in the model of BSI outcome (as noted in Table 3; see
“Results”). However, we did not adjust for multiple testing
and the reason for this is that our original primary hypothesis
relates to investigating the association between autoimmune
disease in the mothers and ASD. Neurodevelopmental and
behavioral outcomes, particularly the collection of BASC
variables, were exploratory. BASC T scores were analyzed
using general linear model adjusted for age and accounting
for within-in family correlation and variation among subjects.
All P reported are two-sided and the signiWcance level is 0.05.
Results
Characteristics of subjects
Characteristics of the mothers and their oVspring with FXS
are illustrated in Tables 1 and 2, respectively. There was no
signiWcant diVerence in mean age between M + AI and
M ¡ AI [40.54 (SD 7.96) vs. 38.62 (SD 6.46) years,
P = 0.238]. There were no signiWcant diVerences in molec-
ular variables including CGG repeats, FMR1 mRNA levels,
and AR between both groups of mothers. The two most
common autoimmune disorders in the mothers were auto-
immune thyroid diseases (27/41, 65.9%), and Wbromyalgia
(11/41, 26.8%). MS and Raynaud’s phenomenon were
present at a similar rate in the mothers at 12.2% (5/41).
Four (4/41, 9.8%) mothers reported to have been diagnosed
with rheumatoid arthritis and three (3/41, 7.3%) mothers
reported having SLE. Other reported autoimmune diseases
included Sjogren syndrome (1/41), optic neuritis (1/41),
and psoriasis for each disease (1/41). Of the 41 M + AI,
there were 29 who presented with a single autoimmune dis-
ease, whereas a further 12 reported having two or more
autoimmune diseases. Twenty (48.8%) mothers had auto-
immune thyroid disease alone and 3 (7.3%) mothers had
been diagnosed with Wbromyalgia alone. In 23 (56.1%)
mothers, the mean age of diagnosis with autoimmune dis-
ease was 30.26 (SD 9.45) years. The remainder of the
group neither recalled the onset of the autoimmune disease
nor the data for the onset of autoimmune disease in medical
records were collected before the association between auto-
immune disease in the mothers and the presence of ASD in
their oVspring with FXS was hypothesized.
Of the 41 mothers, 13 stated that their autoimmune dis-
ease occurred during their gestation. However, a precise
ascertainment of the age of onset or diagnosis for each
autoimmune disease based on self-report was very diYcult
due to the fact that the natural course of many autoimmune
diseases can include a subclinical phase that does not meet
stringent clinical diagnosis (Papi et al. 2007; Poppe and
Glinoer 2003; UlV-Moller et al. 2009).
There was signiWcant diVerence neither in the mean
age of children with FXS in the two groups [9.61 (SD
5.59) vs. 9.41 (SD 6.31) years, in children born of M + AI
and M ¡ AI, respectively, P = 0.836] nor in the type of
the fragile X mutation (percentage of full mutation/
mosaic = 78.7/21.3% vs. 79.4/20.6%, P = 0.876]. With
regard to gender, there were fewer male children with FXS
born to M + AI when compared with children with FXS of
M ¡ AI (60.7 vs. 78.4%, P = 0.016). Mean cognitive abil-
ity in both groups of children with FXS was in a mild
range of intellectual disability and was not signiWcantly
diVerent between groups [FSIQ = 62.75 (SD 17.77) vs.
60.80 (SD 17.55), in children born of M + AI and
M ¡ AI, respectively, P = 0.523]. Likewise, the adaptive
behavior composite score documented by the Vineland
between both groups of children with FXS was not signiW-
cantly diVerent [64.33 (SD 18.51) vs. 63.62 (SD 18.71), in
children born of M + AI and M ¡ AI, respectively,
P =0 . 8 4 7 ] .544 Hum Genet (2010) 128:539–548
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Autoimmune disease, ASD, and other neurodevelopmental 
problems
Of the 61 children with FXS born to M + AI, 38 (62.3%)
children met the criteria for ASD. Twenty-two (36.07%)
subjects had autism and 16 (26.23%) had PDD-NOS. Of
the 32 mothers with children that had FXS and ASD, auto-
immune thyroid disease was present in 22 (67.6%), Wbro-
myalgia in 8 (25.0%), and Raynaud’s phenomenon in 4
(12.5%). Among children from M + AI, the odds ratio (OR)
for FXS and ASD was 1.27 (95% CI 0.62–2.61,
P = 0.5115). These data suggest that autoimmune disease in
the mothers may not be a relevant risk factor for autism in
combination with FXS. Other variables including intellec-
tual disability, sleep problems, and macrocephaly were not
diVerent between both groups of children. However, the
rate of tics was signiWcantly higher in the group of children
with FXS born to M + AI (15/58, 25.86%) compared with
M ¡ AI [10/94, 10.64%; OR = 2.94 (95% CI 1.19–7.24),
p = 0.019].
Autoimmune disease and seizures
Data about seizures were not available for three children.
However, a higher rate of clinical seizures was observed
in a group of children with FXS born to M + AI (9/60,
15.0%) when compared with children with FXS of
M ¡ AI [4/95, 4.21%; OR = 3.81 (95% CI 1.13–12.86),
P = 0.031]. Details of the nine children with FXS who
have seizures and were born to M + AI are as follows: age
range, 4.17–24 years (median age 9 years); gender, 7 boys
and 2 girls; FMR1 mutations, six have the full mutation
and three have mosaicism in the FMR1 gene. Three have
more than one seizures type including complex partial sei-
zures, generalized seizures, gelastic seizures and absence
seizures, four had generalized tonic-clonic convulsions
alone, and two experienced petit mal or absence seizures
alone. Seizures onset ranged from 17 months to 9 years
with a median age of onset at 3 years. With regard to
treatment of seizures, seven subjects reported to take
long-term anticonvulsant medications. Four of these
seven subjects took more than one anticonvulsants to con-
trol the seizures. Of these nine children with FXS born to
M + AI who developed clinical seizures, eight mothers
had autoimmune thyroid disease. There was no history of
birth asphyxia or neonatal encephalopathy. The cognitive
abilities of children with seizures were similar to the whole
group of children with FXS.
Details of four children with FXS who had seizures born
to M ¡ AI are as follows: age range 3.63–17.75 years
(median age 8.25 years), gender 3 boys and 1 girl, all have
the full mutation in the FMR1 gene; one reported to have
more than one seizure type including absence, complex
partial seizures, and generalized seizures, one experienced
absence seizures alone, one had partial seizures alone, and
one subject was noted to have two episodes of simple
febrile seizures but this child has never taken any medica-
tions. Seizures onset in this group ranged from 2.67 to
5 years with a median age of onset at 3.84 years. Abnormal
EEG results were conWrmed in all subjects in this group of
children. With regard to anticonvulsant medications, one
child has taken more than one medication to treat the sei-
zures and seizures were well controlled by one medication
in two subjects in this group.
Autoimmune disease and behavioral problems
Behavioral and emotional problems documented by BASC
were completed in 97 (61.4%) children with FXS in our
study. The children’s age, gender and type of the fragile X
mutations were not signiWcantly diVerent between both
groups (children of M + AI and M ¡ AI). The rate of exter-
nalizing behaviors [36.36 vs. 16.98%; OR = 3.04 (95% CI
1.10–8.38),  P = 0.0319] was increased in children with
FXS born to M + AI. T scores of these behavioral and emo-
tional problems between both groups of children are illus-
trated in Table 4. Children with FXS born to M + AI were
likely to have higher T scores on aggression, internalizing
behaviors, depression, withdrawal symptoms, and BSI
when compared with those children with FXS born to
M ¡ AI, even though only withdrawal symptoms and BSI
scale reached a signiWcant level for documenting the
problems.
Discussion
This is the Wrst study investigating the intergenerational
association between the presence of co-morbid ASD, medi-
cal problems, and behavioral problems in the children with
FXS of M + AI. Evidence of an increased prevalence of
autoimmune disorders including hypothyroidism, Hashim-
oto’s thyroiditis, type 1 diabetes, rheumatoid arthritis, SLE
and ulcerative colitis have been reported in parents of chil-
dren with idiopathic ASD in previous studies (Atladottir
et al.  2009; Comi et al. 1999; Croen et al. 2005; Money
et al.  1971; Mouridsen et al. 2007; Sweeten et al. 2003).
However, this Wnding was not replicated in all studies
(Micali et al. 2004). Our clinical sample of children with
FXS did not support this Wnding. Therefore, autoimmunity
in the mothers may not be signiWcantly associated with
ASD in the oVspring with FXS. A mutation in the FMR1
gene alone involves signiWcant dysregulation of numerous
genes whose translation is controlled by FMRP leading
to signiWcant deWcits in synaptic plasticity and ASD
(Chonchaiya et al. 2009).Hum Genet (2010) 128:539–548 545
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Interesting Wndings were that the rates of seizures, tics,
and externalizing problems documented by the BASC
which were signiWcantly increased in the group of children
with FXS of M + AI. The overall prevalence of seizures in
children with FXS in both groups of M + AI and M ¡ AI
was similar to the 10–20% rate seizures previously reported
in FXS (Berry-Kravis 2002; Musumeci et al. 1999).
The pathophysiology of seizures in those with FXS is
hypothesized to be related to the imbalance of the excit-
atory and inhibitory neurotransmitter systems, especially
the mGluR5 pathway and the gamma-aminobutyric acid A
(GABAA) pathway in the absence of FMRP. There is a
lower expression of GABA receptors in the fragile X knock
out (KO) mouse (D’Hulst et al. 2006) and an increased
expression of glutamic acid decarboxylase (GAD), the
enzyme responsible for GABA synthesis in the KO mouse
(El Idrissi et al. 2005). Interestingly, other factors including
autoimmunity or immune-mediated responses may inXu-
ence these pathways leading to seizures. For instance, the
presence of autoantibody to GAD was demonstrated in the
sera of non-fragile X patients with early onset of chronic
drug-resistant epilepsy leading to loss of GAD and
decreased GABA synthesis that ultimately contributed to a
lower seizure threshold (McKnight et al. 2005). In addition,
autoantibodies to GluR3B-peptide of glutamate/-amino-
3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA)
receptor subtype 3 or to a peptide of N-methyl-D-aspartate
(NMDA) receptor subunit 2A (NR2A) subunit of gluta-
mate/NMDA receptors have been found to be elevated in
non-fragile X patients with epilepsy (Ganor et al. 2005).
However, there are no studies of autoimmunity in mothers
of children with epilepsy or seizures available. Moreover,
the impact of autoimmunity on seizures in individuals with
FXS has not been studied and our work provides just the
Wrst step in this direction. This study suggests that autoim-
munity in the mother may inXuence the risk of seizures in
the oVspring with FXS.
A tic disorder has been reported in approximately 20%
in individuals with FXS (Hagerman 2002). The pathophysi-
ology of tic disorders is quite complex. There are genetic
and environmental inXuences that involve a number of
brain structures including basal ganglia, cortico-striato-
thalamo-cortical circuits, dopaminergic, glutamatergic, and
the serotoninergic neuronal system (Harris and Singer
2006; Rampello et al. 2006). Although there is familial
aggregation in those with Tourette syndrome, the most
severe and chronic form of a tic disorder, but family mem-
bers also share common environmental factors in addition to
their similar genetic backgrounds (O’Rourke et al. 2009).
The potential role of various abnormal immune-mediated
responses followed by diVerent triggers/factors causing or
exacerbating tics or Tourette syndrome has been previously
reported in conditions including PANDAS, possible
involvement of non-streptococcal and viral infection in
aggravating tics symptoms, or the presence of diVerent anti-
bodies/auto-antibodies in either sera or against striatal
Table 4 Parent rating scale 
(T score) of behavioral and 
emotional problems documented 
by BASC between both 
groups of children
Variables Children of mothers 
with autoimmune 
diseases1 
Mean (SD)
Children of mothers 
without autoimmune 
diseases0 
Mean (SD)
N1/N0 P
Externalizing problems 56.5 (12.75) 52.45 (9.02) 44/53 0.072
Hyperactivity 62.64 (14.22) 61.83 (11.36) 44/53 0.757
Aggression 51.68 (12.96) 45.57 (7.77) 44/53 0.005*
Conduct problems 50.13 (12.79) 45.81 (10.37) 30/36 0.104
Internalizing problems 55.14 (11.49) 49.85 (10.02) 44/53 0.016*
Anxiety 52.7 (13.82) 48.51 (10.28) 44/53 0.064
Depression 55.07 (9.7) 50.87 (11.14) 44/53 0.049*
Somatization 55.34 (14.08) 50.55 (10.01) 44/53 0.053
Atypicality 68.23 (15.26) 65.69 (14.66) 43/52 0.405
Withdrawal 73.36 (11.9) 65.21 (12.97) 44/53 0.001*
Attention problems 66.64 (12.98) 65.57 (10.33) 44/53 0.654
Adaptive skills 33.82 (10.91) 34.11 (10.45) 44/53 0.893
Adaptability 38.24 (11.7) 40.83 (10.56) 37/48 0.288
Social skills 39.7 (10.52) 38.51 (12.07) 44/53 0.583
Leadership 34.74 (9.2) 35.81 (9.79) 27/36 0.642
Activities of daily living 33.32 (14.15) 32.65 (11.36) 25/26 0.750
Functional communication 30.35 (11.09) 28.42 (10.47) 26/26 0.639
Behavior symptoms index 65.56 (11.46) 60.29 (10.33) 43/52 0.023*
*S i g n i Wcant at 0.05 level546 Hum Genet (2010) 128:539–548
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structures in human subjects, and animal models, respec-
tively. These antibodies include anti-phospholipid auto-anti-
bodies and antineuronal antibodies (Martino et al. 2009a;
Morer et al. 2008; Rampello et al. 2006). There are no stud-
ies of other autoimmunity in mothers of children with tics or
Tourette syndrome available, although there are family stud-
ies that show a higher incidence of Tourette syndrome in the
parents and the etiology in a subgroup of those with Tourette
syndrome includes autoantibodies against the basal ganglia
as mentioned above so this can also be an autoimmune
disease itself (Martino et al. 2009b; O’Rourke et al. 2009).
Therefore, an increase rate of tics in our study may suggest
another potential hypothesis that future studies should take
into account of autoimmunity in the mothers or the inheri-
tance of autoimmune tendencies in their oVspring with FXS
may be related to a higher rate of tics in these children.
Taken together, our Wndings suggest that future studies
should consider how autoimmunity in the mothers may inter-
act with the FMR1 mutation to disrupt critical networks in
the brain, particularly GABA and glutamate systems or per-
haps through other mechanisms leading to clinical seizures,
tics, and behavioral problems in their oVspring with FXS.
Children with FXS born to M + AI may be genetically more
prone to produce antibodies that exacerbate an underlying
seizure and tic tendency in FXS. This hypothesis requires
further prospective study with larger sample sizes.
The weaknesses of our study includes a clinical sample
with an assessment of autoimmune disease that is docu-
mented only by medical history which can be inXuenced by
poor recall, small numbers of study subjects and the lack of
documentation of speciWc antibodies that may aVect the
oVspring. However, a possible association between the
autoimmunity in mothers and medical and neurodevelop-
mental problems in their children with FXS was assessed
years after our routine data collection and therefore was
blinded and unbiased regarding autoimmune disease in the
mother. Although there were gender diVerences between
both groups of oVspring, other characteristics particularly
age, molecular data, cognitive abilities, and adaptive func-
tioning were not signiWcantly diVerent between both groups
of oVspring. The gender diVerence was accounted for in the
analyses using logistic regression and general linear mod-
els. However, if we had had more male oVspring of
M + AI, it is likely that we would have found more signiW-
cant diVerences between the two groups of children
because boys with FXS have a higher rate of intellectual
and behavioral impairments including autism compared to
girls with FXS.
An important limitation of the current study relates to
our statistically signiWcant Wndings (e.g. seizures, tics, and
BASC behavioral outcome) among our exploratory/second-
ary variables. Although these Wndings suggest speciWc out-
comes to examine in future studies, these statistically
signiWcant  Wndings are not adjusted for multiple testing;
thus, the overall type I error rate is inXated. Mothers pro-
vided data regarding their own medical history and their
oVspring’s behavioral data, it is possible that psychological
factors, such as anxiety or depression associated with auto-
immune disease or the premutation could have introduced a
negative bias in these behavioral ratings. This point, how-
ever, raises another potential explanation for our Wndings,
speciWcally high rates of stress and anxiety associated with
raising children with FXS could potentially contribute to a
pro-inXammatory environment that may facilitate autoim-
munity tendency in the premutation mothers (Stojanovich
2010; Stojanovich and Marisavljevich 2008). The issue
regarding whether or not the autoimmune disease occurred
during the gestation cannot be accurately assessed with this
retrospective data. Therefore, prospectively collected data
is needed to investigate risk during pregnancy and biologi-
cal markers of immune function should be obtained to elu-
cidate this possible intergenerational relationship.
In conclusion, autoimmune disease in mothers was not
signiWcantly associated with the presence of ASD in their
children with FXS. However, clinical seizures, tics, and
behavioral problems were signiWcantly increased in chil-
dren with FXS born to M + AI. These data suggest an addi-
tional mechanism of seizure and tic exacerbation in FXS
related to an intergenerational inXuence from autoimmunity
in the mother.
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